Exosome-Derived miRNAs in Liquid Biopsy for Lung Cancer
2024

Exosome-Derived miRNAs in Liquid Biopsy for Lung Cancer

Sample size: 36 publication 10 minutes Evidence: moderate

Author Information

Author(s): Martínez-Espinosa Israel, Serrato José A., Cabello-Gutiérrez Carlos, Carlos-Reyes Ángeles, Ortiz-Quintero Blanca

Primary Institution: Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas

Hypothesis

Exosome-derived microRNAs (miRNAs) are potential biomarkers for lung cancer detection and monitoring through liquid biopsy.

Conclusion

Exosome-derived miRNAs show promise as valuable biomarkers for the diagnosis, prognosis, and monitoring of lung cancer.

Supporting Evidence

  • Exosome-derived miRNAs are stable in biofluids, making them good candidates for non-invasive diagnostics.
  • Distinct miRNA profiles are observed in lung cancer patients compared to healthy individuals.
  • Liquid biopsies allow for ongoing monitoring of disease progression.

Takeaway

Scientists are studying tiny molecules called miRNAs found in exosomes to help doctors find and track lung cancer without needing to do big surgeries.

Methodology

The review summarizes recent research on exosome-derived miRNAs in liquid biopsies, focusing on studies published in the last five years.

Potential Biases

Variability in miRNA profiles due to factors such as age, lifestyle, and comorbidities may affect results.

Limitations

Most studies rely on small to medium-sized cohorts and lack validation in larger, independent cohorts.

Participant Demographics

The studies included patients with lung adenocarcinoma, squamous-cell lung cancer, and healthy controls.

Statistical Information

P-Value

p = 0.029

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/life14121608

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication